Advent, Columbus lead €22.6m round for Highlight Therapeutics

Columbus invested in the company via its Life Science Fund II, a €70m vehicle that targets Spanish biotechnology companies.

Highlight Therapeutics intends to use the fresh capital to further develop its drug candidate BO-112.

Company
Based in Valencia, Highlight Therapeutics, formerly known as Bioncotech Therapeutics, is a clinical-stage company specialised in immuno-oncology.

Its lead drug candidate BO-112 is a best-in-class RNA-based therapy, able to initiate an immune response in cancer patients, helping those who are resistant to current checkpoint inhibitor therapy.

BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors. In addition to in-house research, Highlight Therapeutics has a number of external collaborators, including partnerships with Merck and UCLA Medical Center.

People
Highlight Therapeutics – Marisol Quintero (CEO).
Columbus Venture Partners –  Damià Tormo (managing partner)

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe
• Healthcare
• Venture
• Spain
• Advent Venture Partners